Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Vyome Holdings, Inc. (NASDAQ: HIND) filings with the U.S. Securities and Exchange Commission, along with AI-powered tools that help interpret the information. Vyome is a clinical-stage healthcare holding company focused on immuno-inflammatory conditions, AI-driven health applications, and AI-enabled medical devices, and its SEC filings offer structured detail on these activities.
Investors can review current reports on Form 8-K, where Vyome discloses material events such as its streamlined Nasdaq listing, financial results for reporting periods, and transactions like the acquisition of substantially all assets of Oculo, Inc. or the announcement of a binding letter of intent involving LiveChain, Inc. and Humanyze. These filings also confirm that Vyome’s common stock, par value $0.001 per share, is listed on The Nasdaq Capital Market under the symbol HIND and that the company qualifies as an emerging growth company.
The definitive proxy statement on Schedule 14A (DEF 14A) is another key document. It describes matters submitted to stockholders at the annual meeting, including the election of Class I directors, approval of the Vyome Holdings, Inc. 2025 Equity Incentive Plan, ratification of the independent registered public accounting firm, and advisory votes on executive compensation. The proxy statement also outlines governance structures and provides context on how the board oversees Vyome’s strategy.
Through this page, users can quickly locate Vyome’s quarterly and annual reports when available, as well as any future registration statements, proxies, or additional 8-Ks that discuss clinical progress for VT-1953 and other programs, capital structure details, or changes in governance. AI-generated summaries highlight the main points in lengthy documents, helping readers understand how specific items—such as equity plans, material transactions, or board decisions—relate to Vyome’s broader focus on immuno-inflammation, AI initiatives, and the US–India innovation corridor.
Vyome Holdings, Inc. is asking stockholders to approve four main items at its 2026 annual meeting on April 24 in New York. Investors will vote to re-elect Venkat Nelabhotla and John Tincoff as Class II directors, approve an advisory “say‑on‑pay” for named executive compensation, and ratify Kreit & Chiu CPA LLP as independent auditor for 2026.
A key proposal would amend the charter to cut authorized common stock from 300,000,000 to 50,000,000 shares. The board says this better matches capital needs, reduces potential dilution concerns and may lower Delaware franchise tax from about $155,000 to about $25,000 for tax years 2026 and 2027. As of March 2, 2026, 7,018,528 common shares were outstanding, with additional shares tied to options, plan reserves and warrants.
The proxy details board structure, committee roles—including a specialized AI Committee—beneficial ownership, and 2025 executive pay, including $478,711 in total compensation for CEO Venkat Nelabhotla. The board unanimously recommends voting FOR all proposals.
Vyome Holdings, Inc. will hold its 2026 Annual Meeting of Stockholders on April 15, 2026 at 12:00 p.m. Eastern Time. The Board set the record date as March 2, 2026 and disclosed 7,018,528 shares of common stock issued and outstanding as of that date.
Stockholders will vote on four proposals: (1) election of two Class II directors (Venkat Nelabhotla and John Tincoff), (2) an amendment to decrease authorized common shares from 300,000,000 to 50,000,000, (3) ratification of Kreit & Chiu CPA LLP as independent auditor, and (4) an advisory vote on executive compensation. The proxy materials and the 2025 Annual Report are being mailed in March 2026.
Vyome Holdings, Inc. (formerly ReShape Lifesciences) is a clinical-stage specialty pharmaceutical company focused on immune‑inflammatory and rare diseases, built around a US‑India R&D corridor. Following an August 2025 merger with Vyome Therapeutics, it now operates biotechnology and pharmaceutical product segments.
The lead candidate, VT‑1953, is a topical gel based on besifloxacin, being developed to treat symptoms of malignant fungating wounds in advanced cancer. Early studies in acne showed low systemic exposure and favorable safety. An investigator‑initiated phase 2 study in malignant fungating wounds reported statistically significant reductions in malodor, pain, and quality‑of‑life impact versus vehicle over 14 days.
Additional programs include VT‑1908, an ophthalmic immune modulator for anterior uveitis at pre‑IND stage, and VB‑1953 for moderate to severe acne, which has completed phase 2 and is described as phase 3‑ready. Vyome also licenses reformulated antifungal products in India through Sun Pharma. As of March 17, 2026, 7,018,528 common shares were outstanding, and non‑affiliate market value at June 30, 2025 was $6.4 million.
Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.
As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.
The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.
Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings, Inc. filed a current report to announce that it released financial results for its third fiscal quarter ended September 30, 2025. On November 18, 2025, the company issued a press release describing these results, which is included as Exhibit 99.1 to this report.
The company notes that the press release and the related information are being furnished, not filed, under securities laws. This means the information carries different legal status and will only be incorporated into other filings if explicitly stated in those future documents.
Vyome Holdings, Inc. (HIND) reported a stock option grant to a director following its merger with Vyome Therapeutics, Inc. Under a previously signed Merger Agreement, Vyome Therapeutics became a subsidiary and the combined company was renamed Vyome Holdings, Inc.
The reporting person received 17,833 stock options to purchase Vyome Holdings common stock at an exercise price of $0.66 per share. Of these, 4,458 options were fully vested on the grant date, while the remaining 13,375 options are scheduled to vest in twelve equal monthly installments beginning on November 30, 2025, contingent on continued service. The grant was made under the company’s 2025 Equity Incentive Plan.
Vyome Holdings, Inc. (HIND) reported a new Form 3 filing for an insider. The filing identifies Stanley D. Pomichter as a director of the company as of 08/15/2025, which is the date of the event requiring this statement. The form is filed by one reporting person and states in the explanation section that no securities are beneficially owned by the reporting person. This means the director reports holding no direct or indirect shares or derivative securities of Vyome Holdings at this time.
Vyome Holdings, Inc. director reports new share ownership following merger. A Form 4 discloses that Mohanjit Jolly, a director of Vyome Holdings (ticker HIND), acquired 454,456 shares of the company’s common stock on 08/15/2025. The shares were received in connection with a merger in which Raider Lifesciences Inc., a wholly owned subsidiary of Vyome Holdings, merged with Vyome Therapeutics, Inc., which became a subsidiary of Vyome Holdings.
Under the merger terms, each 5,000 shares of Vyome Therapeutics common or preferred stock were converted into 1 share of Vyome Holdings common stock. Jolly received the 454,456 Vyome Holdings shares in exchange for 2,272,280,000 shares of Vyome Therapeutics stock. The filing states these shares are held indirectly through Iron Pillar Fund I Ltd., where Jolly is a general partner and an advisor/representative for related investments.